China's medical insurance fund spending on negotiated drugs benefits 1.17B patient visits

​China has carried out negotiations on the National Reimbursement Drug List for eight consecutive years to expand medical insurance coverage, with the medical insurance funds spending 504.8 billion yuan (US$74.04 billion) on medicines under insurance coverage and benefiting 1.17 billion patient visits as of February, an official said Wednesday.

April 16, 2026

China's innovative drugs hit US$130B in overseas licensing in 2025

China is surging in global pharma innovation. One-third of the world's innovative drugs in development come from China, including star anti-cancer treatments like Zanubrutinib and Ivonescimab. In 2025, overseas licensing deals for Chinese innovative drugs soared past US$130 billion, a historic high for the sector, according to a Wednesday briefing.

April 15, 2026

China to improve drug price formation mechanism for reasonable pricing

​The Chinese government has rolled out guidelines on improving the drug price formation mechanism, with the aim of keeping drug prices within a reasonable range.

April 15, 2026